Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema
Open Access
- 6 November 2012
- journal article
- review article
- Published by Springer Nature in International Journal of Emergency Medicine
- Vol. 5 (1) , 39
Abstract
Angioedema is a sudden, transient swelling of well-demarcated areas of the dermis, subcutaneous tissue, mucosa, and submucosal tissues that can occur with or without urticaria. Up to 25% of people in the US will experience an episode of urticaria or angioedema during their lifetime, and many will present to the emergency department with an acute attack. Most cases of angioedema are attributable to the vasoactive mediators histamine and bradykinin. Histamine-mediated (allergic) angioedema occurs through a type I hypersensitivity reaction, whereas bradykinin-mediated (non-allergic) angioedema is iatrogenic or hereditary in origin. Although their clinical presentations bear similarities, the treatment algorithm for histamine-mediated angioedema differs significantly from that for bradykinin-mediated angioedema. Corticosteroids, and epinephrine are effective in the management of histamine-mediated angioedema but are ineffective in the management of bradykinin-mediated angioedema. Recent advancements in the understanding of angioedema have yielded pharmacologic treatment options for hereditary angioedema, a rare hereditary form of bradykinin-mediated angioedema. These novel therapies include a kallikrein inhibitor (ecallantide) and a bradykinin β2 receptor antagonist (icatibant). The physician’s ability to distinguish between these types of angioedema is critical in optimizing outcomes in the acute care setting with appropriate treatment. This article reviews the pathophysiologic mechanisms, clinical presentations, and diagnostic laboratory evaluation of angioedema, along with acute management strategies for attacks.Keywords
This publication has 38 references indexed in Scilit:
- Ecallantide for the Treatment of Hereditary Angiodema in AdultsClinical Medicine Insights: Cardiology, 2011
- Treatment of angiotensin-converting enzyme inhibitor–related angioedema with the bradykinin B2 receptor antagonist icatibantJournal of the American Academy of Dermatology, 2010
- 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedemaAllergy, Asthma & Clinical Immunology, 2010
- HAE therapies: past present and futureAllergy, Asthma & Clinical Immunology, 2010
- Diagnosis and treatment of hereditary angioedema with normal C1 inhibitorAllergy, Asthma & Clinical Immunology, 2010
- Panallergens and their impact on the allergic patientAllergy, Asthma & Clinical Immunology, 2010
- Hereditary AngioedemaNew England Journal of Medicine, 2008
- Nonallergic angioedema: role of bradykininAllergy, 2007
- Hereditary Angioedema: New Findings Concerning Symptoms, Affected Organs, and CourseThe American Journal of Medicine, 2006
- AngioedemaJournal of the American Academy of Dermatology, 2005